Tocilizumab treatment for new onset refractory status epilepticus

New-onset refractory status epilepticus (NORSE) and febrile infection-related epilepsy syndrome (FIRES): State of the art and perspectives

(2018) Nicolas Gaspard et al.   EPILEPSIA

Proposed consensus definitions for new-onset refractory status epilepticus (NORSE), febrile infection-related epilepsy syndrome (FIRES), and related conditions

(2018) Lawrence J. Hirsch et al.   EPILEPSIA

Febrile infection-related epilepsy syndrome treated with anakinra

(2016) Daniel L. Kenney-Jung et al.   ANNALS OF NEUROLOGY

Distinct intrathecal interleukin-17/interleukin-6 activation in anti-N-methyl-d-aspartate receptor encephalitis

(2016) Jung-Ick Byun et al.   JOURNAL OF NEUROIMMUNOLOGY

A clinical approach to diagnosis of autoimmune encephalitis

(2016) Francesc Graus et al.   LANCET NEUROLOGY

Tocilizumab in Autoimmune Encephalitis Refractory to Rituximab: An Institutional Cohort Study

(2016) Woo-Jin Lee et al.   Neurotherapeutics

New-onset refractory status epilepticus

(2015) Nicolas Gaspard et al.   NEUROLOGY

Long-term Therapy With Interleukin 6 Receptor Blockade in Highly Active Neuromyelitis Optica Spectrum Disorder

(2015) Marius Ringelstein et al.   JAMA Neurology

Outcome predictors for status epilepticus—what really counts

(2013) Raoul Sutter et al.   Nature Reviews Neurology

Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial

(2008) Josef S Smolen et al.   LANCET